세계의 생물제제 제조 시장 보고서(2025년)

Biologics manufacturing is the complex process of producing medicines derived from living organisms or their components. It involves cultivating genetically engineered cells or microorganisms in bioreactors to generate therapeutic proteins or other biological products, followed by purification methods such as filtration and chromatography to ensure safety and quality. This process supports the development of safe, effective, and high quality biologic drugs, advancing personalized medicine and improving patient outcomes.

The main modes of manufacturing in biologics manufacturing are contract manufacturing and in-house manufacturing. Contract manufacturing refers to a production approach in which a company assigns the manufacturing of its biologic products to a specialized third party organization. The different modalities include monoclonal antibodies (mAbs), biosimilar and recombinant proteins, vaccines, cell and gene therapies, and ribonucleic acid based therapeutics, and are indicated for oncology, autoimmune disorders, infectious diseases, neurological disorders, and other disease areas.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The biologics manufacturing market research report is one of a series of new reports from The Business Research Company that provides biologics manufacturing market statistics, including biologics manufacturing industry global market size, regional shares, competitors with a biologics manufacturing market share, detailed biologics manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the biologics manufacturing industry. This biologics manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biologics manufacturing market size has grown exponentially in recent years. It will grow from $34.82 billion in 2024 to $42.04 billion in 2025 at a compound annual growth rate (CAGR) of 20.7%. The growth in the historic period can be attributed to rising demand for therapeutic proteins, increasing prevalence of chronic diseases, expanding use of monoclonal antibodies, growing government support for biologics development, and increasing reliance on contract manufacturing organizations.

The biologics manufacturing market size is expected to see exponential growth in the next few years. It will grow to $88.28 billion in 2029 at a compound annual growth rate (CAGR) of 20.4%. The growth in the forecast period can be attributed to rising demand for personalized medicine, increasing investments in cell and gene therapies, growing use of advanced bioprocessing technologies, increasing emphasis on sustainable manufacturing methods, and expanding pipeline of biologic drug candidates. Major trends in the forecast period include a move toward continuous bioprocessing, increasing use of single use technologies, growth in modular biomanufacturing facilities, integration of AI and automation in production, and emphasis on sustainable and green manufacturing approaches.

The rising prevalence of chronic diseases is expected to propel the growth of the biologics manufacturing market going forward. Chronic diseases are persistent health conditions that develop slowly and last for an extended period, often requiring continuous medical care. The growing prevalence of chronic diseases is partly due to inactive lifestyles, as prolonged sitting and minimal physical activity raise the risk of diseases such as heart conditions and diabetes. Biologics manufacturing enhances chronic disease management by producing targeted therapies, making them effective for conditions such as diabetes, cancer, and autoimmune disorders. It reduces disease burden by providing consistent, high quality biologic medicines, improving patient outcomes and treatment efficiency. For instance, in June 2024, according to the National Health Service, a UK based government department, 3615330 individuals registered with a general practitioner were diagnosed with non diabetic hyperglycemia or pre diabetes in 2023, marking an 18 percent increase from 3065825 cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the biologics manufacturing market.

Major companies operating in the biologics manufacturing market are focusing on developing advanced solutions such as integrated biologics contract development and manufacturing organization platforms to enhance end to end biologics development, production efficiency, and supply chain integration across multiple therapeutic modalities. Integrated biologics contract development and manufacturing organization platform refers to a comprehensive framework that combines biologics development, production, and supply services within a single unified system. For instance, in June 2023, Catalent Inc., a US based contract development and manufacturing company, expanded its OneBio Suite for integrated development, manufacturing, and supply across biologic modalities. The enhanced OneBio Suite offers a fully integrated biologics contract development and manufacturing organization platform that supports antibodies, cell and gene therapies, and mRNA based products. It provides end to end services from development to fill finish and packaging through a single contract and harmonized project management, enabling faster development timelines, improved scalability, and seamless global supply integration.

In September 2025, Terumo Corporation, a Japan based medical technology company, acquired WuXi Biologics Cayman Inc. for an undisclosed amount. Through this acquisition, Terumo aims to expand its contract development and manufacturing organization production capacity and global presence, enhancing its ability to provide integrated biologics manufacturing and fill finish services for injectable therapies. WuXi Biologics Cayman Inc. is a China based company offering end to end solutions for the discovery, development, and manufacturing of biologics.

Major companies operating in the biologics manufacturing market are Johnson & Johnson, F. Hoffmann La-Roche Ltd., Pfizer Inc, AbbVie Inc., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., LG Life Sciences Ltd., Novo Nordisk A/S, Amgen Inc., FUJIFILM Holdings Corporation, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Lonza Group Ltd., Intas Pharmaceuticals Ltd., Samsung Biologics Co. Ltd., Fareva SA, Celltrion Inc., Evotec SE

North America was the largest region in the biologics manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biologics manufacturing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biologics manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biologics manufacturing market consists of sales of therapeutic proteins, enzymes, recombinant DNA products, blood factors, and other biologic-based therapeutics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biologics Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biologics manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biologics manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biologics manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Mode of Manufacturing: Contract Manufacturing; In-House Manufacturing
• 2) By Modality: Monoclonal Antibodies (mAbs); Biosimilar And Recombinant Proteins; Vaccines (recombinant/mRNA/Viral); Cell And Gene Therapies; Ribonucleic Acid-Based Therapeutics
• 3) By Disease Indication: Oncology; Autoimmune Disorders; Infectious Diseases; Neurological Disorders; Other Disease Indications
• Subsegments:
• 1) By Contract Manufacturing: Mammalian Cell-Based Production; Microbial Fermentation Production; Cell-Free Protein Synthesis; Hybrid Manufacturing Systems
• 2) By In-House Manufacturing: Mammalian Cell Culture Production; Microbial Expression Systems; Continuous Bioprocessing; Single-Use Technology Production
• Companies Mentioned: Johnson & Johnson; F. Hoffmann La-Roche Ltd.; Pfizer Inc; AbbVie Inc.; Eli Lilly and Company; Novartis AG; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; LG Life Sciences Ltd.; Novo Nordisk A/S; Amgen Inc.; FUJIFILM Holdings Corporation; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Lonza Group Ltd.; Intas Pharmaceuticals Ltd.; Samsung Biologics Co. Ltd.; Fareva SA; Celltrion Inc.; Evotec SE
• Countries:

Table of Contents

1. Executive Summary

2. Biologics Manufacturing Market Characteristics

3. Biologics Manufacturing Market Trends And Strategies

4. Biologics Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Biologics Manufacturing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biologics Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biologics Manufacturing Market Growth Rate Analysis
• 5.4. Global Biologics Manufacturing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biologics Manufacturing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biologics Manufacturing Total Addressable Market (TAM)

6. Biologics Manufacturing Market Segmentation

• 6.1. Global Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Contract Manufacturing
• In-House Manufacturing
• 6.2. Global Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies (mAbs)
• Biosimilar And Recombinant Proteins
• Vaccines
• Cell And Gene Therapies
• Ribonucleic Acid-Based Therapeutics
• Others Modalitys
• 6.3. Global Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Autoimmune Disorders
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disorders
• Other Disease Indications
• 6.4. Global Biologics Manufacturing Market, Sub-Segmentation Of Contract Manufacturing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammalian Cell-Based Production
• Microbial Fermentation Production
• Cell-Free Protein Synthesis
• Hybrid Manufacturing Systems
• 6.5. Global Biologics Manufacturing Market, Sub-Segmentation Of In-House Manufacturing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammalian Cell Culture Production
• Microbial Expression Systems
• Continuous Bioprocessing
• Single-Use Technology Production

7. Biologics Manufacturing Market Regional And Country Analysis

• 7.1. Global Biologics Manufacturing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biologics Manufacturing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biologics Manufacturing Market

• 8.1. Asia-Pacific Biologics Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biologics Manufacturing Market

• 9.1. China Biologics Manufacturing Market Overview
• 9.2. China Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biologics Manufacturing Market

• 10.1. India Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biologics Manufacturing Market

• 11.1. Japan Biologics Manufacturing Market Overview
• 11.2. Japan Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biologics Manufacturing Market

• 12.1. Australia Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biologics Manufacturing Market

• 13.1. Indonesia Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biologics Manufacturing Market

• 14.1. South Korea Biologics Manufacturing Market Overview
• 14.2. South Korea Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biologics Manufacturing Market

• 15.1. Western Europe Biologics Manufacturing Market Overview
• 15.2. Western Europe Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biologics Manufacturing Market

• 16.1. UK Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biologics Manufacturing Market

• 17.1. Germany Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biologics Manufacturing Market

• 18.1. France Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biologics Manufacturing Market

• 19.1. Italy Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biologics Manufacturing Market

• 20.1. Spain Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biologics Manufacturing Market

• 21.1. Eastern Europe Biologics Manufacturing Market Overview
• 21.2. Eastern Europe Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biologics Manufacturing Market

• 22.1. Russia Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biologics Manufacturing Market

• 23.1. North America Biologics Manufacturing Market Overview
• 23.2. North America Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biologics Manufacturing Market

• 24.1. USA Biologics Manufacturing Market Overview
• 24.2. USA Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biologics Manufacturing Market

• 25.1. Canada Biologics Manufacturing Market Overview
• 25.2. Canada Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biologics Manufacturing Market

• 26.1. South America Biologics Manufacturing Market Overview
• 26.2. South America Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biologics Manufacturing Market

• 27.1. Brazil Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biologics Manufacturing Market

• 28.1. Middle East Biologics Manufacturing Market Overview
• 28.2. Middle East Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biologics Manufacturing Market

• 29.1. Africa Biologics Manufacturing Market Overview
• 29.2. Africa Biologics Manufacturing Market, Segmentation By Mode of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biologics Manufacturing Market, Segmentation By Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biologics Manufacturing Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biologics Manufacturing Market Competitive Landscape And Company Profiles

• 30.1. Biologics Manufacturing Market Competitive Landscape
• 30.2. Biologics Manufacturing Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann La-Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Biologics Manufacturing Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Bristol-Myers Squibb Company
• 31.3. Thermo Fisher Scientific Inc.
• 31.4. LG Life Sciences Ltd.
• 31.5. Novo Nordisk A/S
• 31.6. Amgen Inc.
• 31.7. FUJIFILM Holdings Corporation
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Lonza Group Ltd.
• 31.11. Intas Pharmaceuticals Ltd.
• 31.12. Samsung Biologics Co. Ltd.
• 31.13. Fareva SA
• 31.14. Celltrion Inc.
• 31.15. Evotec SE

32. Global Biologics Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biologics Manufacturing Market

34. Recent Developments In The Biologics Manufacturing Market

35. Biologics Manufacturing Market High Potential Countries, Segments and Strategies

• 35.1 Biologics Manufacturing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biologics Manufacturing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biologics Manufacturing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer